Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 31 to 39 of 39

Publication Record


AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives.
Viollet B, Guigas B, Leclerc J, H├ębrard S, Lantier L, Mounier R, Andreelli F, Foretz M
(2009) Acta Physiol (Oxf) 196: 81-98
MeSH Terms: AMP-Activated Protein Kinases, Aminoimidazole Carboxamide, Animals, Dyslipidemias, Energy Metabolism, Fatty Liver, Gluconeogenesis, Glucose, Homeostasis, Humans, Hypoglycemic Agents, Lipid Metabolism, Liver, Liver Cirrhosis, Mitochondria, Protein Conformation, Protein Subunits, Ribonucleotides
Show Abstract · Added April 17, 2014
As the liver is central in the maintenance of glucose homeostasis and energy storage, knowledge of the physiology as well as physiopathology of hepatic energy metabolism is a prerequisite to our understanding of whole-body metabolism. Hepatic fuel metabolism changes considerably depending on physiological circumstances (fed vs. fasted state). In consequence, hepatic carbohydrate, lipid and protein synthesis/utilization are tightly regulated according to needs. Fatty liver and hepatic insulin resistance (both frequently associated with the metabolic syndrome) or increased hepatic glucose production (as observed in type 2 diabetes) resulted from alterations in substrates oxidation/storage balance in the liver. Because AMP-activated protein kinase (AMPK) is considered as a cellular energy sensor, it is important to gain understanding of the mechanism by which hepatic AMPK coordinates hepatic energy metabolism. AMPK has been implicated as a key regulator of physiological energy dynamics by limiting anabolic pathways (to prevent further ATP consumption) and by facilitating catabolic pathways (to increase ATP generation). Activation of hepatic AMPK leads to increased fatty acid oxidation and simultaneously inhibition of hepatic lipogenesis, cholesterol synthesis and glucose production. In addition to a short-term effect on specific enzymes, AMPK also modulates the transcription of genes involved in lipogenesis and mitochondrial biogenesis. The identification of AMPK targets in hepatic metabolism should be useful in developing treatments to reverse metabolic abnormalities of type 2 diabetes and the metabolic syndrome.
0 Communities
1 Members
0 Resources
18 MeSH Terms
Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia.
Gutierrez DA, Puglisi MJ, Hasty AH
(2009) Curr Diab Rep 9: 26-32
MeSH Terms: Adipocytes, Adipose Tissue, Apoptosis, Cell Differentiation, Chemokines, Dyslipidemias, Humans, Inflammation, Insulin, Insulin Resistance, Leptin, Obesity, Signal Transduction, T-Lymphocytes
Show Abstract · Added December 5, 2013
Obesity is associated with increased prevalence of metabolic disorders, such as inflammation, insulin resistance, and dyslipidemia, which can predispose an individual to develop diabetes and cardiovascular disease. Adipose tissue (AT) is now recognized as a metabolically active organ that controls plasma free fatty acid levels and contributes to systemic metabolic homeostasis by secreting adipokines. In obesity, the recruitment of immune cells, such as T cells and macrophages, to AT causes inflammation, which is thought to contribute to local insulin resistance. This loss of insulin sensitivity within AT can lead to uncontrolled release of fatty acids, secretion of inflammatory cytokines, and alterations in the balance of adipokines, which ultimately impact lipoprotein metabolism and insulin sensitivity systemically. Thus, AT itself plays an important role in the increased risk of diabetes and cardiovascular disease that is associated with obesity.
1 Communities
1 Members
0 Resources
14 MeSH Terms
Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice.
Braun Na, Wade NS, Wakeland EK, Major AS
(2008) Lupus 17: 1070-8
MeSH Terms: Animals, Antibodies, Antiphospholipid, Atherosclerosis, Autoimmunity, Cholesterol, LDL, Cholesterol, VLDL, DNA, Dietary Fats, Dyslipidemias, Lipoproteins, LDL, Lupus Erythematosus, Systemic, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Receptors, LDL
Show Abstract · Added February 11, 2014
Individuals suffering from systemic lupus erythematosus (SLE) are predisposed to accelerate cardiovascular disease. Our laboratory has recently developed an animal model of SLE-accelerated atherosclerosis. We have shown that, following 8 weeks feeding high fat Western diet, radiation chimeras consisting of SLE-derived haematopoietic cells transferred to low-density lipoprotein (LDL)r(-/-) mice (LDLr.Sle) have increased atherosclerosis compared with C57Bl/6 bone marrow recipients (LDLr.B6). However, this feeding regimen resulted in significant mortality in SLE-susceptible mice compared with controls with surviving animals having extremely elevated serum cholesterol (>500 mg/dL) and increased serum markers of kidney pathology. To test the hypothesis that SLE-associated autoimmune dysregulation can exacerbate atherosclerosis under more mild serum cholesterol conditions (approximately 200 mg/dL), we examined SLE and lesion development in radiation chimeras fed either a normal chow or high fat Western diet for 8 weeks. High fat fed LDLr.Sle mice exhibited increased mortality and were significantly more hypertensive. LDLr.Sle mice had greater titres of antibodies against dsDNA, oxLDL and phospholipid compared with controls. Lupus-susceptibility increased the atherosclerotic lesions and the percentage of CD4(+) T cells in the lesions of proximal aortas, independent of diet. These data show that increased dyslipidemia resulting from high-fat feeding can exacerbate autoimmunity and associated vascular complications. Conversely, they also show that autoimmune dysregulation can accelerate atherosclerosis in LDLr-deficient animals independent of feeding high fat diet. Collectively this study provides additional evidence that the accelerated atherosclerosis observed in SLE is autoimmune associated.
0 Communities
1 Members
0 Resources
15 MeSH Terms
The cumulative effect of core lifestyle behaviours on the prevalence of hypertension and dyslipidemia.
Villegas R, Kearney PM, Perry IJ
(2008) BMC Public Health 8: 210
MeSH Terms: Alcohol Drinking, Blood Pressure, Cardiovascular Diseases, Cross-Sectional Studies, Diet, Dyslipidemias, Exercise, Family Practice, Female, Health Behavior, Humans, Hypertension, Ireland, Life Style, Male, Middle Aged, Prevalence, Risk Factors, Smoking, Surveys and Questionnaires
Show Abstract · Added December 10, 2013
BACKGROUND - Most cardiovascular disease (CVD) occurs in the presence of traditional risk factors, including hypertension and dyslipidemia, and these in turn are influenced by behavioural factors such as diet and lifestyle. Previous research has identified a group at low risk of CVD based on a cluster of inter-related factors: body mass index (BMI) < 25 Kg/m2, moderate exercise, alcohol intake, non-smoking and a favourable dietary pattern. The objective of this study was to determine whether these factors are associated with a reduced prevalence of hypertension and dyslipidemia in an Irish adult population.
METHODS - The study was a cross-sectional survey of 1018 men and women sampled from 17 general practices. Participants completed health, lifestyle and food frequency questionnaires and provided fasting blood samples for analysis of glucose and insulin. We defined a low risk group based on the following protective factors: BMI <25 kg/m2; waist-hip ratio (WHR) <0.85 for women and <0.90 for men; never smoking status; participants with medium to high levels of physical activity; light alcohol consumption (3.5-7 units of alcohol/week) and a "prudent" diet. Dietary patterns were assessed by cluster analysis.
RESULTS - We found strong significant inverse associations between the number of protective factors and systolic blood pressure, diastolic blood pressure and dyslipidemia. The prevalence odds ratio of hypertension in persons with 1, 2, 3, > or = 4 protective factors relative to those with none, were 1.0, 0.76, 0.68 and 0.34 (trend p < 0.01). The prevalence odds ratio of dyslipidemia in persons with 1, 2, 3, > or = 4 protective factors relative to those with none were 0.83, 0.98, 0.49 and 0.24 (trend p = 0.001).
CONCLUSION - Our findings of a strong inverse association between low risk behaviours and two of the traditional risk factors for CVD highlight the importance of 'the causes of the causes' and the potential for behaviour modification in CVD prevention at a population level.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
Ali YS, Linton MF, Fazio S
(2008) Curr Opin Endocrinol Diabetes Obes 15: 142-6
MeSH Terms: Clinical Trials as Topic, Diabetes Complications, Diabetic Angiopathies, Dyslipidemias, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipoproteins, Risk Factors
Show Abstract · Added December 10, 2013
PURPOSE OF REVIEW - The management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk.
RECENT FINDINGS - A number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events.
SUMMARY - Aggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.
0 Communities
1 Members
0 Resources
8 MeSH Terms
Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
Atkinson RD, Coenen KR, Plummer MR, Gruen ML, Hasty AH
(2008) Am J Physiol Endocrinol Metab 294: E284-90
MeSH Terms: Adipose Tissue, Animals, Apolipoproteins E, Atherosclerosis, Blotting, Western, Body Composition, Bone Marrow Transplantation, Dyslipidemias, Leptin, Lipids, Lipoproteins, Macrophages, Mice, Mice, Knockout, Obesity, Reverse Transcriptase Polymerase Chain Reaction
Show Abstract · Added December 5, 2013
Previous studies have demonstrated that macrophage-derived apolipoprotein E (apoE) reduces atherosclerotic lesion formation in lean apoE-deficient ((-/-)) mice. apoE has also been demonstrated to play a role in adipocyte differentiation and lipid accumulation. Because the prevalence of obesity has grown to epidemic proportions, we sought to determine whether macrophage-derived apoE could impact atherosclerotic lesion formation or adipose tissue expansion and inflammation in obese apoE(-/-) mice. To this end, we transplanted obese leptin-deficient (ob/ob) apoE(-/-) mice with bone marrow from either ob/ob;apoE(-/-) or ob/ob;apoE(+/+) donors. There were no differences in body weight, total body adipose tissue, or visceral fat pad mass between recipient groups. The presence of macrophage-apoE had no impact on adipose tissue macrophage content or inflammatory cytokine expression. Recipients of apoE(+/+) marrow demonstrated 3.7-fold lower plasma cholesterol (P < 0.001) and 1.7-fold lower plasma triglyceride levels (P < 0.01) by 12 wk after transplantation even though apoE was present in plasma at concentrations <10% of wild-type levels. The reduced plasma lipids reflected a dramatic decrease in very low density lipoprotein and a mild increase in high-density lipoprotein levels. Atherosclerotic lesion area was >10-fold lower in recipients of ob/ob;apoE(+/+) marrow (P < 0.005). Similar results were seen in leptin receptor-deficient (db/db) apoE(-/-) mice. Finally, when bone marrow transplantation was performed in 4-mo-old ob/ob;apoE(-/-) and db/db;apoE(-/-) mice with preexisting lesions, recipients of apoE(+/+) marrow had a 2.8-fold lower lesion area than controls (P = 0.0002). These results demonstrate that macrophage-derived apoE does not impact adipose tissue expansion or inflammatory status; however, even very low levels of macrophage-derived apoE are capable of reducing plasma lipids and atherosclerotic lesion area in obese mice.
1 Communities
2 Members
0 Resources
16 MeSH Terms
Dietary chickpeas reverse visceral adiposity, dyslipidaemia and insulin resistance in rats induced by a chronic high-fat diet.
Yang Y, Zhou L, Gu Y, Zhang Y, Tang J, Li F, Shang W, Jiang B, Yue X, Chen M
(2007) Br J Nutr 98: 720-6
MeSH Terms: Adiposity, Animals, Cicer, Dietary Fats, Dyslipidemias, Insulin Resistance, Male, Obesity, Rats, Rats, Sprague-Dawley, Treatment Outcome
Show Abstract · Added May 9, 2010
The improved effects of dietary chickpeas on visceral adiposity, dyslipidaemia and insulin resistance were examined. Rats were fed a normal-fat diet (NFD), a high-fat diet (HFD) or a high-fat plus chickpea diet (HFD+CP) for 8 months. The epididymal fat pad weight v. total body weight of rats was higher in the HFD group (0.032 (sd 0.0042) g/g) than in the NFD group (0.015 (sd 0.0064) g/g) and smaller in the HFD+CP group (0.023 (sd 0.0072) g/g) compared with the HFD group (P < 0.05). Chickpea treatment also induced a favourable plasma lipid profile reflecting decreased TAG, LDL-cholesterol (LDL-C) and LDL-C:HDL-cholesterol levels (P < 0.05). HFD-fed rats had higher TAG concentration in muscle and liver, whereas the addition of chickpeas to the HFD drastically lowered TAG concentration (muscle, 39 %; liver, 23 %). The activities of lipoprotein lipase (LPL) in epididymal adipose tissue and hepatic TAG lipase in liver recorded a 40 and 23 % increase respectively in HFD rats compared with those in NFD rats; dietary chickpeas completely normalised the levels. Furthermore, chickpea-treated obese rats also showed a markedly lower leptin and LPL mRNA content in epididymal adipose tissue. An insulin tolerance test, oral glucose tolerance test and insulin-releasing test showed that chickpeas significantly improved insulin resistance, and prevented postprandial hyperglycaemia and hyperinsulinaemia induced by the chronic HFD. The present findings provide a rational basis for the consumption of chickpeas as a functional food ingredient, which may be beneficial for correcting dyslipidaemia and preventing diabetes.
0 Communities
1 Members
0 Resources
11 MeSH Terms
Mechanisms of progression of chronic kidney disease.
Fogo AB
(2007) Pediatr Nephrol 22: 2011-22
MeSH Terms: Adolescent, Child, Chronic Disease, Disease Progression, Dyslipidemias, Female, Fibrosis, Genetic Predisposition to Disease, Humans, Hypertension, Renal, Kidney Diseases, Male, Podocytes, Polymorphism, Genetic, Proteinuria, Renin-Angiotensin System, Transforming Growth Factor beta
Show Abstract · Added January 20, 2012
Chronic kidney disease (CKD) occurs in all age groups, including children. Regardless of the underlying cause, CKD is characterized by progressive scarring that ultimately affects all structures of the kidney. The relentless progression of CKD is postulated to result from a self-perpetuating vicious cycle of fibrosis activated after initial injury. We will review possible mechanisms of progressive renal damage, including systemic and glomerular hypertension, various cytokines and growth factors, with special emphasis on the renin-angiotensin-aldosterone system (RAAS), podocyte loss, dyslipidemia and proteinuria. We will also discuss possible specific mechanisms of tubulointerstitial fibrosis that are not dependent on glomerulosclerosis, and possible underlying predispositions for CKD, such as genetic factors and low nephron number.
1 Communities
1 Members
0 Resources
17 MeSH Terms
Interplay between apolipoprotein E and scavenger receptor class B type I controls coronary atherosclerosis and lifespan in the mouse.
Fazio S, Linton MF
(2005) Circulation 111: 3349-51
MeSH Terms: Animals, Apolipoproteins E, Coronary Artery Disease, Dyslipidemias, Lipid Metabolism, Lipoproteins, Longevity, Mice, Mice, Knockout, Scavenger Receptors, Class B
Added May 27, 2014
0 Communities
1 Members
0 Resources
10 MeSH Terms